Implantable cardioverter defibrillator for primary prevention in patients with non-ischemic cardiomyopathy in the era of novel therapeutic agents- meta-analysis

BACKGROUND: Evidence regarding the mortality benefit of implantable cardioverter defibrillator (ICD) non-ischemic dilated cardiomyopathy (NIDCM) is inconsistent. The most recent randomized study, the DANISH trial, did not find improved outcomes with ICD. However, based on previous studies and meta-a...

Descripción completa

Detalles Bibliográficos
Autores principales: Kolben, Yotam, Hirsh Raccah, Bruria, Koev, Ivelin, Luria, David, Amir, Offer, Biton, Yitschak
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Cardiovascular Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10240391/
https://www.ncbi.nlm.nih.gov/pubmed/37283572
http://dx.doi.org/10.3389/fcvm.2023.1192101

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10240391/
https://www.ncbi.nlm.nih.gov/pubmed/37283572
http://dx.doi.org/10.3389/fcvm.2023.1192101

Ejemplares similares